Treatment of high risk human papillomavirus infection in low grade cervical squamous intraepithelial lesion with mild local thermotherapy Three case reports
Treatment of high risk human papillomavirus infection in low grade cervical squamous intraepithelial lesion with mild local thermotherapy Three case reports
复制标题
轻度局部热疗治疗高危人乳头瘤病毒感染低度宫颈鳞状上皮内病变3例报告
DOI：
10.1097/md.0000000000021005
复制
发表时间：
2020-07-02
期刊：
影响因子：
1.6
通讯作者：
Gao, Xing-Hua
中科院分区：
文献类型：
--
作者：
Yang, Yang;Zhang, Lan;Gao, Xing-Hua
简介：44℃局部轻度热疗已被证实对人乳头瘤病毒（HPV）诱发的皮肤疣有效，但对高危型HPV引起的宫颈上皮内瘤变（CIN）的疗效尚未见报道。患者关注：本研究报告了3例低级别CIN和阳性高危型HPV （HPV 16、31、52、56、58）患者。诊断：诊断是基于HPV类型的鉴定和异常细胞学结果。干预措施：3例患者采用陶瓷加热（表面温度44℃）至宫颈局部热疗。治疗连续3天，每天1次，10 +/- 3天后再加2次类似治疗，每次持续30分钟。3个月后进行HPV和细胞学检查。结果：3例患者细胞学检查均恢复正常。2例患者HPV阴性，其余治疗前HPV 56和58阳性患者变为单独HPV58阳性。结论：本初步观察提示，经合格的RCT验证，局部轻度热疗可作为治疗持续性HPV感染CIN患者的一种新方法。
Introduction: Mild local hyperthermia at 44 degrees C has been proven efficacious in the treatment of cutaneous warts induced by human papillomavirus (HPV), while its effect on cervical intraepithelial neoplasia (CIN) caused by high risk type of HPVs has not been reported. Patient concerns: Three patients with low grade CIN and positive high risk HPV types (HPV 16, 31, 52, 56, 58)are reported in this study. Diagnosis: The diagnosis was based on identification of HPV types and abnormal cytological findings. Interventions: The 3 patients were treated with local hyperthermia from ceramic heating (surface temperature, 44 degrees C) to cervix. The treatment was delivered once a day for 3 consecutive days, plus two similar treatments 10 +/- 3 days later, with each session lasting 30 minutes. HPV and cytology test were performed 3 months thereafter. Outcomes: All the 3 patients recovered to normal cytological findings. Two of the patients were negative for HPV, the remaining patient with pre-treatment HPV 56 and 58 positivity changed to HPV58 positive alone. Conclusion: This pilot observation inspires that mild local hyperthermia be recommended as a new method in the treatment of CIN patients with persistent HPV infection, once validated by qualified RCT.